X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC LTD with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs ACTAVIS (US) - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC LTD   ACTAVIS
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
ACTAVIS
Dec-14
ALEMBIC LTD/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs7218,752-   
Low Rs3411,438-   
Sales per share (Unadj.) Rs4.73,376.8-  
Earnings per share (Unadj.) Rs6.1-421.4-  
Cash flow per share (Unadj.) Rs6.2309.8-  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.77,324.1-  
Shares outstanding (eoy) m267.03265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.5 252.0%   
Avg P/E ratio x8.7-35.8 -24.2%  
P/CF ratio (eoy) x8.548.7 17.4%  
Price / Book Value ratio x1.32.1 63.2%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1394,013,841 0.4%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m2070-   
Avg. sales/employee Rs ThNM41,568.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-5,187.3-  
INCOME DATA
Net Sales Rs m1,255897,882 0.1%  
Other income Rs m370-2,241 -16.5%   
Total revenues Rs m1,625895,641 0.2%   
Gross profit Rs m111115,346 0.1%  
Depreciation Rs m38194,424 0.0%   
Interest Rs m228,321 0.0%   
Profit before tax Rs m442-109,640 -0.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-8,043 0.0%   
Tax Rs m24-5,637 -0.4%   
Profit after tax Rs m1,630-112,046 -1.5%  
Gross profit margin %8.912.8 68.9%  
Effective tax rate %5.45.1 105.4%   
Net profit margin %129.8-12.5 -1,040.5%  
BALANCE SHEET DATA
Current assets Rs m1,867473,069 0.4%   
Current liabilities Rs m591345,006 0.2%   
Net working cap to sales %101.614.3 712.7%  
Current ratio x3.21.4 230.3%  
Inventory Days Days9458 162.5%  
Debtors Days Days7466 111.0%  
Net fixed assets Rs m1,791109,640 1.6%   
Share capital Rs m5340-   
"Free" reserves Rs m10,3240-   
Net worth Rs m10,8581,947,473 0.6%   
Long term debt Rs m411,020,514 0.0%   
Total assets Rs m11,5913,569,077 0.3%  
Interest coverage x260.9-2.9 -9,085.7%   
Debt to equity ratio x00.5 0.7%  
Sales to assets ratio x0.10.3 43.0%   
Return on assets %14.1-2.3 -600.1%  
Return on equity %15.0-5.8 -260.9%  
Return on capital %15.2-3.0 -504.5%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Net fx Rs m-2440-   
CASH FLOW
From Operations Rs m236154,184 0.2%  
From Investments Rs m-224-369,175 0.1%  
From Financial Activity Rs m-27207,423 -0.0%  
Net Cashflow Rs m-15-7,568 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.74 Rs / USD

Compare ALEMBIC LTD With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALEMBIC LTD With: DISHMAN PHARMA  DR. DATSONS LABS  TORRENT PHARMA  BIOCON LTD  GLENMARK PHARMA  



Today's Market

Of IPOs, LIC-IDBI Bank Deal, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed marginally higher on Friday last week. All sectoral indices traded in green, with stocks in the IT sector and stocks in the pharma sector, leading the gains.

Related Views On News

ALEMBIC LTD Announces Quarterly Results (4QFY18); Net Profit Up 64.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC LTD has posted a net profit of Rs 46 m (up 64.9% YoY). Sales on the other hand came in at Rs 332 m (up 0.9% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Jul 20, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS